Skip to main content
Premium Trial:

Request an Annual Quote

Almac Gets CLIA OK for Lab

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Almac Diagnostics today said that it has received CLIA certification for a new lab it has opened to support its biomarker discovery and development strategy.

Craigavon, Northern Ireland-based Almac said that the lab will support its own needs as well as those of its pharmaceutical partners.

"We have come to a point where the biomarkers we have discovered and assays that we have developed are being used to stratify patients, enrich clinical trials, and impact patient treatment decisions," Paul Harkin, president and managing director of Almac’s Diagnostics business, said in a statement. "As such, CLIA is a key necessity for the processing of these samples."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.